Department of Pathology, The Medical College of Wisconsin, and Children's Wisconsin, Wauwatosa, Wisconsin, USA.
J Clin Microbiol. 2024 Aug 14;62(8):e0070324. doi: 10.1128/jcm.00703-24. Epub 2024 Jul 2.
The clinical microbiology laboratory is capable of identifying microorganisms in clinical specimens faster and more accurately than ever before. At face value, this should enable patient care providers to make better-informed decisions and target antimicrobial therapies to deliver individualized care. Ironically, more complete and specific reporting of microorganisms isolated from specimens may result in overtreatment based on the presence of a pathogen, even in the absence of clear signs of clinical infection. This conundrum calls into question the role of the laboratory in contributing to care through selective or "exception" reporting whereby some results are selectively withheld when there is a low probability that laboratory findings correlate with the clinical infection. In a recent article published in the , Bloomfield et al. (J Clin Microbiol 62:e00342-24, 2024, https://doi.org/10.1128/jcm.00342-24) examine the impact and safety of an exception reporting strategy applied to wound swab specimens. Canonical pathogens associated with skin and soft tissue infections including and beta-hemolytic streptococci are withheld from the laboratory report if certain patient criteria are met that would put them at low risk of adverse outcomes if untreated, or if treated with guideline-recommended empiric therapy. Their central finding was an approximately 50% reduction in post-laboratory report antibiotic initiation without adverse events or increased 30-day admission rate (indicative of infection-related complications, e.g., disseminated disease). While effectively achieving their goal, the premise of exception reporting and other modified reporting strategies raises questions about the potential risk of underreporting and how to ensure that the message is being interpreted, and acted upon, by care providers as was intended by the laboratory.
临床微生物学实验室能够以前所未有的速度和准确性鉴定临床标本中的微生物。从表面上看,这应该使患者护理提供者能够做出更明智的决策,并针对抗菌治疗,提供个体化的护理。具有讽刺意味的是,从标本中分离出的微生物的更完整和更具体的报告可能会导致过度治疗,即使没有明确的临床感染迹象,这是基于病原体的存在。这种困境使得实验室在通过选择性或“例外”报告来促进护理的作用受到质疑,即在实验室结果与临床感染相关性较低的情况下,选择性地保留一些结果。在最近发表在《临床微生物学杂志》上的一篇文章中,Bloomfield 等人(J Clin Microbiol 62:e00342-24, 2024, https://doi.org/10.1128/jcm.00342-24)研究了一种应用于伤口拭子标本的例外报告策略的影响和安全性。如果符合某些患者标准,即如果未经治疗或根据指南推荐的经验性治疗,他们的不良后果风险较低,或者患有与皮肤和软组织感染相关的典型病原体,包括金黄色葡萄球菌和β-溶血性链球菌,则不会在实验室报告中报告这些病原体。他们的主要发现是,在没有不良事件或增加 30 天入院率(表明感染相关并发症,例如播散性疾病)的情况下,大约减少了 50%的实验室报告后抗生素起始率。虽然这种例外报告策略及其它改良报告策略有效地实现了他们的目标,但例外报告的前提和其它修改后的报告策略引发了一些问题,即潜在的漏报风险,以及如何确保信息被护理提供者解释和遵循,就像实验室所预期的那样。